All the news

A new form of pegylated interferon is associated with significantly fewer side-effects than the standard form of the drug, a study conducted in patients with the easier-to-treat hepatitis C genotypes shows. Data from ...

Twice as many HIV-positive gay men are now being infected with hepatitis C as HIV-positive injecting drug users, a Swiss study presented to the 19th Retrovirus Conference has found.New hepatitis ...

The rollout of antiretroviral therapy in resource-limited settings provides a model for efforts to increase access to hepatitis C treatment and care in similar settings, investigators argue in the online edition of Clinical ...

Drug-drug interactions between direct-acting antiviral agents for hepatitis C and some antiretroviral medications used to treat HIV are common, but are often modest and can be managed with dose adjustments when treating people ...

An interferon-free combination of the experimental polymerase inhibitor GS-7977 plus ribavirin potently and rapidly reduced hepatitis C virus (HCV) levels, but almost all patients experienced viral rebound after they stopped treatment, researchers reported ...

Adding a first-generation hepatitis C virus (HCV) protease inhibitor to pegylated interferon/ribavirin dramatically increases the likelihood of 12-week sustained virological response to hepatitis C treatment among HIV/HCV coinfected people, researchers reported on Tuesday at ...

Hepatitis C treatment responses in patients co-infected with HIV are better in patients infected with hepatitis C subtype-1b than 1a, according to Spanish research published in the online edition of the ...

First-line hepatitis C therapy which includes a protease inhibitor can be cost-effective, investigators show in the Annals of Internal Medicine. The study showed that a triple combination of drugs, including the cheaper ...

Deaths in the US due to hepatitis C now exceed those caused by HIV, according to research published in the Annals of Internal Medicine.  The study showed that there is a ...